AACI/SIRUM Webinar | Leveraging Oncology Surplus Medicine for Good
New date and time! Monday, August 10, 1:00 pm ET
Every year in the United States, $11 billion worth of perfectly good, unopened medicine goes to waste. A surplus of $2 billion comes directly from oncology, yet the majority of cancer patients struggle with their high prescription costs. There are programs across the country that work to facilitate the donation and reuse of this surplus through repositories and charitable pharmacies. SIRUM—a national drug donation expert—works with policymakers, drug repository programs, and cancer centers to help facilitate this redistribution. To date, SIRUM has redistributed more than $350 million worth of prescription medications.
Presenters: George Wang, PhD, SIRUM; Heather Jones, PharmD, MS, Cleveland Clinic; Jennifer Booth, PharmD, MS, BCPS, The Ohio State University Wexner Medical Center
Webinars are hosted on the Medlive platform and open to all AACI members. Registration is free with the creation of a Medlive account. Please contact AACI Program Manager Hailey Honeycutt with any questions.
AACI Update | August 2026
Headlines
Baskin Named VCU Massey Director
Monica L. Baskin, PhD, will serve as the next director of VCU Massey Comprehensive Cancer Center. Dr. Baskin is the first female director of Massey and the first Black woman to be named director of a National Cancer Institute (NCI)-Designated Cancer Center. As the fifth director of Massey since its NCI designation in 1975, she oversees a comprehensive cancer center made up of 250 scientists and clinical investigators. Dr. Baskin succeeds AACI Immediate Past President Robert A. Winn, MD.
Annual Meeting Spotlight: Working Effectively With Colleagues of All Ages
At 8:30 am central time on Monday, October 26, panelists will share strategies for collaboration, engagement, and closing the generation gap at work during "Four Generations, One Workplace: Navigating the Post-COVID Cancer Center Workforce." The session is part of the 2026 AACI/CCAF Annual Meeting, slated for October 25-27 in Chicago.
The James Hosts Second Clinical Trial Concept Workshop in Partnership With AACI
Photo credit: Randy Belice
The Ohio State University Comprehensive Cancer Center - The James hosted the in-person component of its "Clinical Trial Concept in the Oncology Landscape" course for the second consecutive year, during the 18th Annual AACI CRI Meeting. The hybrid course, known as the idea2Concept Workshop, teaches oncology fellows, residents, and junior faculty to apply good clinical practice and scientific reasoning in clinical trial design.
AACI Comments on Proposed OMB Grant Rule, Shares Opportunities for Federal Engagement
Last month AACI submitted comments to the White House Office of Management and Budget (OMB) in response to its proposed Regulation for Federal Financial Assistance (OMB-2026-0034). The association is currently reviewing additional federal policy proposals that could impact academic cancer centers, including a potential cap on the number of active grants a principal investigator can hold and provisions related to the 340B Drug Pricing Program and site-neutral payment policies.
Learn How SIRUM is Redistributing Surplus Oncology Medicine 'for Good'
Pictured, clockwise from top right: Drs. George Wang, Heather Jones, and Jennifer Booth
At 1:00 pm eastern time on Monday, August 10, AACI will host a webinar in partnership with SIRUM, titled "Leveraging Oncology Surplus Medicine for Good." Presenters George Wang, PhD; Heather Jones, PharmD, MS; and Jennifer Booth, PharmD, MS, BCPS will share how surplus medicine donation works — and how it's already changing lives.
News from the Centers
Gabrilove Receives 2026 Lifetime Achievement Award
Mount Sinai Tisch Cancer Center
Janice Gabrilove, MD, received the 2026 Lifetime Achievement Award from the Icahn School of Medicine at Mount Sinai Faculty Council in recognition of her leadership, innovation, mentorship, and impact in oncology and medicine.
Bergom Named ASTRO Fellow
Siteman Cancer Center
Carmen Bergom, MD, PhD, a WashU Medicine radiation oncologist at Siteman Cancer Center, has been named a fellow of the American Society for Radiation Oncology (ASTRO).Ulrich Among Huntsman's New and Renewed Endowed Chairs
Huntsman Cancer Institute at the University of Utah
AACI Vice President/President-elect Cornelia Ulrich, MS, PhD, is one of seven Huntsman Cancer Institute faculty members recently honored with an endowed chair. Dr. Ulrich, chief scientific officer and executive director of Huntsman's Comprehensive Cancer Center, has been appointed the inaugural Mary C. Beckerle Presidential Endowed Chair in Cancer Research and Leadership.
Markey Named Innovators Network Endowed Chair
Fred Hutch Cancer Center
Kate Markey, MBBS, PhD, FRACP, a Fred Hutch physician who studies how bacteria in the gut affect recovery after patients receive a bone marrow transplant or cellular immunotherapy, has been named the next holder of the Innovators Network Endowed Chair. The chair is awarded every three years to an early-career scientist whose work demonstrates creativity, collaboration, innovation, and strong potential for patient impact.
Researcher Awarded $3.4M NCI Grant for Stem Cell-Based Breast Cancer Prevention
UF Health Cancer Institute
With a $3.4 million, five-year R01 grant from the National Cancer Institute, UF Health Cancer Institute member Lusine Yaghjyan, MD, PhD, will explore how breast stem cells contribute to the early stages of breast tumor development.Research Team Receives $3.2M NCI Grant to Cascade Genetic Testing to Relatives
University of Michigan Rogel Cancer Center
A research team led by Steven J. Katz, MD, MPH, and Lawrence C. An, MD, at Rogel Cancer Center and Allison Kurian, MD, MSc, at Stanford University received a $3.2 million grant from the National Cancer Institute (NCI) to expand Genetic Information and Family Testing (GIFT), a program helping cancer patients with hereditary mutations share risk information with relatives. Using the NCI Surveillance Epidemiology and End Results registry, researchers will reach out to nearly 4,000 cancer survivors diagnosed in Georgia and California. Enrolled patients will invite first- and second-degree relatives to receive online education and low-cost home genetic testing.
NIH Awards $3.1 Million for Pancreatic Cancer Research
LSU LCMC Health Cancer Center
LSU Health New Orleans has received a five-year, $3.1 million National Institutes of Health (NIH) grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center. Samarpan Majumder, PhD, associate professor in the Department of Genetics, and Rinku Majumder, PhD, professor in the Department of Interdisciplinary Oncology, will examine the role of Protein S, a physiological anticoagulant, in tumor growth and thrombosis associated with pancreatic cancer.
Study Explores Effects of Weight-Loss Drugs on Colorectal Cancer Risk
The University of Kansas Cancer Center
The National Cancer Institute (NCI) awarded Jennifer Davis, PhD, of The University of Kansas Cancer Center, a two-year R21 grant to study how obesity, metabolism, and the widely used weight-loss drug tirzepatide affect colorectal cancer risk. Using the iKAP mouse model in obese mice, researchers will examine the drug's effects both before and after tumors begin. With about 11 percent of Americans reporting use of weight-loss drugs, the study aims to clarify safety and prevention implications for future clinical guidance.
Cynthia Ma Receives Susan G. Komen Leadership Grant
Siteman Cancer Center
Cynthia X. Ma, MD, PhD, a WashU Medicine physician-scientist at Siteman Cancer Center, has received a leadership grant from Susan G. Komen to advance breast cancer research focused on endocrine resistance, a major challenge in treatment for hormone receptor-positive breast cancer.
RevitaLash Cosmetics Award Accelerates Karmanos, Wayne State Cancer Research
Karmanos Cancer Institute, Wayne State University
The lab of Asfar Azmi, PhD (pictured, far left), received a $250,000 RevitaLash Cosmetics Gayle Brinkenhoff Excellence in Cancer Research Award to investigate whether drugs that inhibit cancerous growth in KRAS and PCNA may be more effective when administered together. Dr. Azmi is the director of the Pancreatic Cancer Research Initiative at Karmanos Cancer Institute.
Gadgeel Named Co-Chair of Winship PRMC
Winship Cancer Institute of Emory University
Shirish Gadgeel, MBBS, FASCO, has been named co-chair of the Protocol Review and Monitoring Committee (PRMC) at Winship Cancer Institute. Together with Pediatric Oncologist Tamara Miller, MD, MSCE, Gadgeel will lead the PRMC in ensuring rigorous internal oversight of Winship’s cancer clinical trials, a requirement for all National Cancer Institute-Designated Cancer Centers.
Shah Named Associate Director for Translational Research
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Pediatric oncologist Nirali N. Shah, MD, MHSc, has been named associate director for translational research for the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center and will serve as professor and director of the Pediatric/Adolescent and Young Adult Cell and Gene Therapy Program at University of Maryland School of Medicine.
Zhong Appointed Director of Hollings CMI Shared Resource
Hollings Cancer Center, Medical University of South Carolina
Zhi Zhong, MD, PhD, has been appointed director of the MUSC Hollings Cancer Center Cell and Molecular Imaging (CMI) Shared Resource. Dr. Zhong will provide scientific, operational, and strategic leadership and help ensure delivery of state-of-the-art imaging, expertise, and training. She succeeds John Lemasters, MD, PhD, who retired after 20 years at MUSC.
Internationally Recognized Hematologist to Treat Patients at UMGCCC
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Hematologist Enrico M. Novelli, MD, MS, has been named director of the University of Maryland School of Medicine Program in Sickle Cell Disease and a professor in the Department of Medicine, Division of Hematology/Oncology. He will treat patients at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC).
Munster Appointed to Expand Impact of Stanford's Early Drug Development Program
Stanford Cancer Institute
Pamela Munster, MD, has joined the Stanford Cancer Institute as the inaugural associate director for Early Detection and Interception Research. Dr. Munster brings her expertise in translational medicine, early-phase clinical trials, and precision oncology to Stanford’s Early Drug Development Program, helping turn scientific discoveries into safer, more personalized treatments for patients.
Stanford Scientists Develop Novel Solution for Tonic Signaling in CAR T Cells
Stanford Cancer Institute
Tonic CAR signaling is one of the biggest hurdles limiting CAR T therapy's success in solid tumors. Taking inspiration from nature, Jeremy Bjelajac, PhD, a postdoctoral scholar in the lab of Crystal Mackall, MD, developed a platform modeled on the immune system's native self-regulation to cut off tonic signaling at the source.
Wearable Devices May Help Detect Cytokine Release Syndrome Earlier
Mount Sinai Tisch Cancer Center
Researchers at Mount Sinai Tisch Cancer Center have found that wearable devices may help clinicians detect cytokine release syndrome—a common and potentially serious side effect of CAR T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma. The findings, published in JCI Insight, could help expand CAR T therapy into outpatient and community-based settings, improving access for patients who live far from major cancer centers.
Antiviral Immune Defenses Repurposed to Attack Tumors
Fox Chase Cancer Center, Temple Health
By studying how viruses trigger cell death, Siddharth “Sid” Balachandran, PhD, and his team uncovered mechanisms that could help the immune system recognize and destroy cancer cells that would otherwise go unnoticed. This finding, that antiviral immune defenses can be repurposed to attack tumors, reflects a deeper philosophy about how scientific breakthroughs happen.
IU Study: Obesity 'Fuels' Leukemia, Combo Using Popular Weight-Loss Drugs May Stop It
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Obesity can act as fuel for leukemia, according to a study led by Indiana University School of Medicine and IU Simon Comprehensive Cancer Center scientists. To help many patients facing aggressive blood cancers overcome this metabolic risk, researchers identified a potential new treatment strategy that combines popular weight-loss medications with anti-inflammatory drugs. The findings were recently published in the Journal of Clinical Investigation.
Winship Researchers Engineer 'Armored' CAR T Cells to Improve Tumor Control
Winship Cancer Institute of Emory University
Researchers at Winship Cancer Institute have developed an "armored" form of CAR T-cell therapy designed to remain active longer and recruit additional immune cells to help attack cancer. The findings, published in Science Translational Medicine, could provide a new strategy for overcoming some of the most persistent barriers limiting CAR T-cell therapy, particularly for solid tumors.
Roswell Park Team Discovers Metabolic Pathway in Cell Nucleus That Helps Cancer Progress
Roswell Park Comprehensive Cancer Center
A Roswell Park team has identified a novel metabolic pathway that plays a key role in enabling cancer to progress through gene activation. In a new study in the journal Nature Communications, the researchers show that shutting down the pathway can seriously impair the ability of tumor cells to multiply and spread. Subhamoy Dasgupta, PhD, co-leader of the Cancer Stress Biology Program at Roswell Park, is the study's senior author.
Bile Acid Buildup Can Drive Spread of Breast Cancer
University of Virginia Cancer Center
UVA Cancer Center researchers found bile acid buildup caused by an unhealthy gut microbiome can cause breast inflammation and drive metastasis of hormone receptor-positive (HR+) breast cancer, the most common form of metastatic breast cancer. Mouse studies and a review of human patient data showed elevated bile acids were associated with reduced survival, and patients on existing FDA-approved bile acid sequestrants tended to live longer. Published in Cancer Research, the findings suggest a possible prevention strategy for HR+ breast cancer metastasis.Gut Bacteria Metabolites Help Immune System Fight Cancer
Cedars-Sinai Cancer
Cedars-Sinai Cancer researchers have identified indoles, metabolites produced by gut bacteria, that help the immune system fight cancer. In mouse studies, indole restricted growth of melanoma and colon, breast, and pancreatic cancers, outperforming related metabolites already used in immunotherapies. Human patients responding well to immunotherapy for melanoma also showed higher levels of indole-producing enzymes. Investigators are evaluating whether increasing gut indole levels could be useful in future anticancer therapies.
JAMA Review Outlines How Obesity Leads to Cancer
The University of Kansas Cancer Center
Ten percent of new cancer diagnoses in the United States are linked to being overweight or obese, and losing at least 10 percent of body weight may be necessary to lower risks, according to a JAMA review coauthored by KU Cancer Center's Kristy Brown, PhD, and collaborators from Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Winship Cancer Institute of Emory University.
LIG1 Loss Exposes Therapeutic Vulnerability in Triple-Negative Breast Cancer
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers with TP53 mutations drives chemotherapy-resistance. A team of researchers at the Dan L Duncan Comprehensive Cancer Center and collaborating institutions identified a vulnerability in these cells and used it to their advantage, combining available drugs to reduce tumor growth in animal models. The findings, published in Molecular Cancer Therapeutics, position LIG1 status as a potential biomarker for future clinical trials.Newly Identified Inhibitors May Boost Drug's Ability to Fight Treatment-Resistant Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Scientists at Johns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center say they have found a potential therapeutic target that can boost the potency of decitabine, a chemotherapy used to treat certain cancers. In a study published in Proceedings of the National Academy of Sciences, they found that blocking the function of a protein called DCTPP1 with newly identified inhibitors helped improve decitabine’s ability to kill off of prostate cancer cells.
Roswell Park Documents High Success Rate for Allogeneic Stem Cell Transplants
Roswell Park Comprehensive Cancer Center
A new Roswell Park study found that standardizing donor transplant protocols led to a 92.6-percent one-year survival rate for allgeneic stem cell transplant patients, well above the 80 percent national benchmark. Changes included less toxic treatment regimens, standardized patient-donor matching, and post-transplant cyclophosphamide to prevent graft-versus-host disease. The approach also expanded access to patients historically not considered good candidates, including those over age 60, and implemented an early-discharge outpatient care model.
Some Metastatic Breast Cancer Patients May Benefit From More Aggressive Treatment
Duke Cancer Institute
A Duke Cancer Institute study led by Jennifer Plichta, MD, found patients with oligometastatic breast cancer—limited-spread Stage IV disease—who had their primary tumor surgically removed had better survival than those who did not. Published in JAMA Surgery, the retrospective study suggests increased personalization and a curative-intent approach may be beneficial for some metastatic breast cancer patients.
Study Reveals Why Some Colorectal Cancers Respond Better to Immunotherapy
USC Norris Comprehensive Cancer Center
A new study from Keck School of Medicine of USC uncovers why certain colorectal cancers, specifically those with microsatellite instability and deficient DNA mismatch repair, respond more favorably to immunotherapy. The researchers identified a biological feedback loop involving two key genes, Death Receptor 5 ( and Ligase 3, which play a crucial role in driving tumor cell death and galvanizing the immune system’s attack on these tumors. These discoveries could pave the way for enhancing immunotherapy effectiveness and personalizing treatment plans for patients with colorectal cancer.
UF Researchers Discover First-of-Its-Kind Compound to Target Lung Cancer Cells
UF Health Cancer Institute
UF Health Cancer Institute researchers discovered the first compound to effectively target GRP78, a heat shock protein hijacked by cancer cells to survive stress. Screening nearly 700 molecules, the team found the compound, called compound 12, killed lung cancer cells by inhibiting GRP78 in lab testing and in mice. Published in Angewandte Chemie International Edition, the findings could lead to new drug targets and biomarkers for lung cancer treatment.Common Thyroid Hormone May Help Prevent Brain Tumor Relapse in Children
Fox Chase Cancer Center, Temple Health
Researchers from Fox Chase Cancer Center have identified a widely used thyroid hormone that may significantly improve treatment outcomes for medulloblastoma, the most common malignant brain tumor in children. The study found that adding triiodothyronine, an FDA‑approved hormone used to treat hypothyroidism, to standard chemotherapy could help prevent tumors from growing back after treatment. The findings were published in the journal Cell Press.
Could These Tiny Organs Save Millions of Lives?
UCSF Helen Diller Family Comprehensive Cancer Center
Organoids, once seen mainly as research tools, are now emerging as promising platforms for developing drugs and tailoring treatments. In the Rosenbluth lab at UCSF, research is underway to test the effectiveness of different chemotherapies, trace the influence of the environment on disease, and compare healthy brain cells to those with disorders.Engineered Gut Bacteria Show Promise Against Pancreatic Cancer
The University of Chicago Medicine Comprehensive Cancer Center
In a new study published in Science Advances, researchers at the University of Chicago report a promising new strategy to overcome the "cold" tumor microenvironment using BifidoSumIL-2, an engineered bacterial strain of Bifidobacterium longum, a probiotic bacterium naturally found in the gut, to deliver an immune-stimulating therapy directly inside tumors. The study highlights BifidoSumIL-2 as a potentially powerful approach for improving treatment response in pancreatic cancer.FDA Approves New Breast Cancer Drug Based on VIKTORIA-1 Study Results
Fred Hutch Cancer Center
The U.S. Food and Drug Administration (FDA) recently approved the drug gedatolisib, a multi-targeted kinase inhibitor capable of squelching numerous parts of a key signaling pathway often co-opted by cancer to drive tumor growth and treatment resistance in patients. Fred Hutch's Sara Hurvitz, MD, led the multicenter VIKTORIA-1 trial as part of the drug's development and said it could be a "potential new standard of care."
Study Explains How Colorectal Cancer Cells Maintain High Iron Levels
University of Michigan Rogel Cancer Center
Rogel Cancer Center researchers discovered a key metabolic pathway that allows colorectal cancer cells to survive toxic iron levels: a mitochondrial complex called complex II that buffers iron-induced cell death by regulating coenzyme Q. Knocking out complex II killed cancer cells in cell lines and mouse models with few side effects, suggesting it could be a promising new drug target.
Breast Cancer Rising Fast in Asian American Women
UCSF Helen Diller Family Comprehensive Cancer Center
A new study led by UC San Francisco has found an alarming rise in invasive breast cancer among Asian American women over the last two decades. The study, published in JAMA Network Open, found that breast cancer incidence increased by more than 3 percent per year in nearly every Asian American ethnic group, and it rose even higher for Chinese and Vietnamese women.
New Drug Shows Promise for NRAS-Driven Melanoma
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute researchers found NRAS-driven melanoma samples were responsive to daraxonrasib, a drug that recently doubled survival in a pancreatic cancer clinical trial. The results were published in Cancer Research, a journal of the American Association for Cancer Research.
Yoga Eases Anxiety, Mood Symptoms in Cancer Survivors
Wilmot Cancer Institute, UR Medicine
UR Medicine researchers have discovered a yoga intervention goes a step further than other therapies to improve physical and psychological side effects that most patients with cancer experience. The new study points to a single, non-drug approach that empowers cancer survivors to reduce stress and boost overall health as they graduate from primary treatments like surgery and chemotherapy.
Assessment Shows How Long Patients Wait for Test Results
Hollings Cancer Center, Medical University of South Carolina
An assessment led by MUSC Hollings lung cancer pulmonologist Adam Fox, MD, and supported, in part, by the American Cancer Society National Lung Cancer Roundtable, showed that the time from biopsy to biomarker results is about twice as long as most doctors think it is. The findings were published in JCO Oncology Practice.
Family History Increases Cancer Risk in BRCA-Tested Patients
Cedars-Sinai Cancer
Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by Cedars-Sinai Health Sciences University investigators. The findings, published in JAMA Network Open, highlight how strongly family history contributes to cancer risk.
Experimental KRAS Vaccine Generates Immune Responses Against Pancreatic Cancer in People at High Risk
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk. Findings from the Phase I clinical trial were published in Cancer Discovery, a journal of the American Association for Cancer Research.
Thymus-Derived Hormone May Help Suppress Age-Related Inflammation
USC Norris Comprehensive Cancer Center
A new study suggests the thymus-derived hormone thymulin may enhance cancer treatment outcomes in older patients. Researchers have found that as thymulin levels decline with age, chronic inflammation linked to diseases like cancer and heart disease increases. This research opens new avenues for understanding the connection between aging, inflammation, and age-related diseases like cancer.
Cancer Research Pioneer Gary Morrow Dies at 82
Wilmot Cancer Institute, UR Medicine
Gary R. Morrow, PhD, MS, died on July 7, at age 82, of pneumonia complications after coping with prostate cancer for 16 years. A longstanding leader at Wilmot Cancer Institute, Dr. Morrow was credited with building the science around easing cancer symptoms and side effects, such as nausea.
Mobile Lung Screening Unit Reaches 1,000 Patients, Expands Access Across Rural Indiana
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indiana’s first mobile lung screening program has reached a major milestone, screening its 1,000th patient since launching in March 2025. The IU Health Mobile Lung Screening Unit has visited 45 counties, expanding access to lifesaving lung cancer screening across the state, particularly in rural communities.
Markey Celebrates 'Topping Out' of New Cancer Center
UK Markey Cancer Center
Clinicians, faculty, and staff gathered last month to sign the final steel beam before it was raised into place atop the new 550,000-square-foot building that will house the UK Markey Cancer Center. The new facility, which will also house a comprehensive spine center, ambulatory surgery space, and other outpatient services, is slated to open in 2028. Markey Director B. Mark Evers, MD, a member of AACI's Board of Directors, delivered remarks.
Dana-Farber Launches Free, Evidence-Based Tool for Evaluating Cancer-Related Claims
Dana-Farber Cancer Institute, Harvard Medical School
Dana-Farber Cancer Institute has updated the Cancer FactFinder, a free online resource providing evidence-based information on what does and does not cause cancer. The site presents the best evidence currently available in clear, accessible language, making it a valuable tool to share with affiliates, colleagues, students, and community partners. The resource launched in 2022 to combat cancer-related misinformation. Currently available in English, it will soon expand to eight additional languages.Karmanos Rolls Out New KCI Clinical Trials App Features
Karmanos Cancer Institute, Wayne State University
Karmanos Cancer Institute (KCI) has released a new and improved version of the KCI Clinical Trials App with new features to improve usability, accessibility, and alignment with today’s clinical and cancer research workflows. The upgrades provide a modernized platform to improve how patients, caregivers, and health care professionals discover and engage with actively recruiting cancer clinical trials, leading to more informed treatment decisions.
Conversations in Cancer: Radioligand Therapy
Duke Cancer Institute
Radioligand therapy is an image-guided cancer treatment that uses radioactive material to selectively target and destroy cancer cells. In the Duke Health's Conversations in Cancer series, Diane Reidy-Lagunes, MD, and Hannah McManus, MD, Duke Cancer Institute oncologists specializing in neuroendocrine tumors and prostate cancer, respectively, discuss ongoing research to improve and expand radioligand therapy to more cancer types.
Subaru Dealerships Donate Care Kits and Comfort Items for UVA Cancer Center Patients
University of Virginia Cancer Center
UVA Cancer Center received donations of comfort items and care kits from local Subaru dealerships. The gifts were part of the Subaru Loves to Care initiative, a nationwide partnership with Blood Cancer United (formerly The Leukemia & Lymphoma Society) dedicated to providing comfort, encouragement, and support to individuals and families affected by blood cancer.Cancer Center Jobs
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Read moreMeeting Announcements
AACI/SIRUM Webinar: Leveraging Surplus Medicine for Good
Save the Date: Annual Gastrointestinal Oncology Symposium
Save the date for the Annual Gastrointestinal Oncology Symposium, hosted by Karmanos Cancer Institute. The symposium is geared towards general physicians, surgeons, fellows, residents, students, pathologists, radiation oncologists, pharmacists, physician assistants, nurse practitioners, and nurses in the field of hematology and oncology. Please contact Pamela Sydorchuk, symposium coordinator, at [email protected] or call 313-576-8746 with any questions.
Cancer Center Community Impact Forum
The Cancer Center Community Impact Forum (CCCIF) is a national annual meeting of NCI Designated Cancer Center professionals and professionals at cancer centers working towards designation who are dedicated to advancing community-engaged cancer control. The meeting is hosted by the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium.
2026 AACI Leadership Development Workshop
The 2026 AACI Leadership Development Workshop will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
This event convenes emerging leaders for didactic and experiential leadership development sessions. An offshoot of Dr. Caryn Lerman’s AACI presidential initiative, the workshop aims to enhance the oncology leadership pipeline with top talent.
Support Opportunities
2026 Impact Summit
The 2026 Impact Summit will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
Co-hosted by AACI and the Cancer Center Network, the Impact Summit brings together cancer center leaders, researchers, and other stakeholders for a dynamic one-day event focused on strengthening the future of cancer center leadership and workforce development.
Support Opportunities
2026 New Cancer Center Directors Meeting
The 2026 New Cancer Center Directors Meeting will be held in conjunction with the 2026 AACI/CCAF Annual Meeting. Participation in this meeting is by invitation only.
2026 AACI/CCAF Annual Meeting
The 3-day AACI/CCAF annual meeting offers AACI members the opportunity to network with cancer center colleagues, national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.
Support Opportunities
Save the Date: 2027 AACI/AACR Hill Day
Save the date for the 2027 AACI/AACR Hill Day. More information to come.
Save the Date: 19th Annual AACI CRI Meeting
Save the date for the 19th Annual AACI Clinical Research Innovation (CRI) Meeting, June 28-30, 2027, at the Loews Chicago O'Hare Hotel in Rosemont, IL.